Board of Directors
Our board of directors is composed of highly experienced individuals in the pharmaceutical industry, finance and governance.
Come work at Theratechologies
Theratechnologies is constantly looking for talented, energetic people that share our values.
Chair of the Board
Ms. Dawn Svoronos worked in the commercial side of the business for the multinational pharmaceutical company Merck & Co. Inc., for 23 years, retiring in 2011. From 2009 to 2011, Ms. Svoronos was President of the Europe/Canada region for Merck and from 2006 to 2009 was President of Merck in Canada. Previously held positions with Merck include Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise.
Ms. Svoronos sits on the Boards of Directors of PTC Therapeutics in New Jersey and Xenon Pharmaceuticals Inc. in Burnaby, British Columbia.
Luc Tanguay, M.Sc., CFA
President and Chief Executive Officer
Mr. Luc Tanguay has a long-standing experience and an enviable reputation in the finance and biotechnology sectors. Named President and Chief Executive Officer in 2012, he has been central to the strategy to buy back rights to EGRIFTA® in 2014, which allowed the Corporation to build its commercial platform. Since 1996, Mr. Tanguay has held various upper management positions at Theratechnologies, including Executive Vice President and Chief Financial Officer. Mr. Tanguay started his career in investment banking at Lévesque Beaubien (now National Bank Financial) where he helped several corporations to become publicly traded.
Mr. Tanguay holds a Bachelor’s and a Master’s degree in Finance from Université de Sherbrooke. He also obtained his Chartered Financial Analyst title from the University of Virginia.
Gérald A. Lacoste, c.r.
Mr. Gérald A.Lacoste is a retired lawyer with extensive experience in the fields of securities regulation, corporate finance and corporate governance. He was previously Chairman of the Québec Securities Commission (now known as the Autorité des marchés financiers) and was also President and Chief Executive Officer of the Montreal Stock Exchange.
During his career, Mr. Lacoste acted as a legal counsel to the Canadian Standing Senate Committee on Banking, Trade and Commerce, he chaired the Québec Advisory Committee on Finanacial Institutions, and was a member of the task force on the capitalization of life insurance companies in Québec.
Mr. Lacoste is currently a corporate director and is a member of the North American Free Trade Agreement(NAFTA) arbitrat on panel.
Paul Pommier, MBA
Mr. Paul Pommier spent over 25 years at National Bank Financial, his last position being Senior Executive Vice President, Corporate and Government Finance.
Throughout his career, he oversaw public and private financings, mergers and acquisitions, as well as the marketing of investment offerings. Retired since 1997, Mr. Pommier acted as Chairman of the Board of Theratechnologies between 2007 and 2013.
Dale Weil, MBA
Ms. Dale Weil has more than 35 years of experience in the commercialization, marketing, sale of consumer products and B2B services. She spent the last 17 years of her career in management positions related to health care services such as distribution, pharmaceutical and retail pharmacy services.
She has been working with McKesson Canada Corporation (“McKesson”) since August 1999 where she occupied the position of Vice President and Senior Vice President for various divisions of McKesson. She has been acting in an advisor role to the President since May 2015. Prior to May 2015, she acted as Senior Vice President Retail Banner Management Services with McKesson from July 2014 to May 2015 and, from November 2011 to June 2014, she acted as Senior Vice President, Integrated Health Care Solutions, Strategy and Business Development with McKesson.
Ms. Weil holds a Master in Business Administration from McGill University and has obtained her certification as a certified director after successfully completing the ICD Directors Education Program.
Gary Littlejohn, MBA, LL.B.
From 2008 to 2015, Mr. Littlejohn held the position of CEO and then of advisor to the Chairman and Board Member of the Arab National Investment Company, also known as ANB Invest, in Riyadh, a subsidiary of Arab National Bank. Previously, he was Managing Director of investment banking at Desjardins Securities in Montreal, a position he took after serving six years as Executive Vice-president at Ecopia Biosciences. Mr. Littlejohn also occupied various senior positions in investment banking at TD Securities, Midland Walwyn, BMO Nesbitt Burns and National Bank Financial. Most recently, he held the position of Interim CEO at Helix BioPharma. Mr. Littlejohn also served on the Board of several corporations including Helix BioPharma, ANB Invest, Aegera Pharmaceuticals, Ecopia Biosciences and The Montreal Exchange.
Mr. Littlejohn holds a B.A. (Honours Economics), a BCL and a MBA from McGill University. He also completed the Director Education Program provided by the Canadian Institute of Corporate Directors in 2016. He is a retired lawyer of the Quebec Bar.
Sheila M. Frame, MBA
Ms. Frame is currently Vice President and Head Biopharmaceuticals, North America at Sandoz Inc. (a division of Novartis) in the United States.
Previously, she successively held the positions of Worldwide General Manager, Immunoscience, Worldwide Commercial Lead, Opdivo® new indications and Biomarker diagnostics, Worldwide Commercial Lead Yervoy® from the US and Vice President, specialty business at Bristol-Myers Squibb in Canada. She was also called upon to occupy several senior roles at UCB Inc. and at AstraZeneca in Canada, the US and the Nordics.
Ms. Frame completed the requirements for the Chartered Corporate Director program with the Director’s college in 2006. She also completed a Masters of Business Administration at Concordia University in Montreal and she holds a Bachelor of Arts from York University in Toronto.